HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICCVAM Plans For Alternative Skin-Sensitization Tests

This article was originally published in The Rose Sheet

Executive Summary

The Interagency Coordinating Committee on the Validation of Alternative Test Methods says it is developing a plan to help it evaluate and advance alternative tests for skin sensitization at a time when skin allergies are a growing concern.

You may also be interested in...

ECHA: Registrants Using Skin Sensitization Alt Methods Should Update Dossiers Using OECD 497

The agency is aware of more than 14,000 substances on the EU market with some indication of skin-sensitization concern. Using the OECD guideline, adopted in June, registrants may be able to make conclusive predictions without use of animals and should update REACH dossiers accordingly.

“Humane Cosmetics Act” Seeks End To Cosmetic Animal Testing In U.S.

Introduced in the House March 5 by Rep. Jim Moran, D-Va., HR 4148 seeks to ban the sale of cosmetics tested on animals, or containing ingredients tested on animals, three years after the bill’s enactment. Cruelty Free International is calling for the legislation’s “swift passage” to protect animals and align the U.S. with global regulatory trends.

ICCR Addresses Lead Limit, Endocrine Disruptors At 7th Meeting

Regulators from the US, Canada, Japan and the EU met in Tokyo July 8-10 for the seventh annual meeting of the International Cooperation on Cosmetics Regulation. The group agreed to recommend a 10-ppm limit on lead in cosmetic products.

Related Content

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts